Blab Tech
Zomato Founder Deepinder Goyal Unveils Temple Wearable, Claims New Entropy Metric Tracks Meditation Recovery
When the founder of India’s most popular food‑delivery platform steps out of the kitchen and into the lab, he brings a new kind of headgear: Temple.
Temple is a forehead‑mounted sensor that the co‑founder of Zomato, Deepinder Goyal, says is the world’s smallest wearable. The bean‑shaped device sits on the temple area and promises to deliver real‑time data on focus, fatigue and cognitive performance by measuring cerebral blood flow and oxygenation. Goyal, who earned EY’s Entrepreneur of the Year award in 2025, has long pursued longevity research. He describes Temple as an experimental offshoot of his Gravity Aging Hypothesis work.
The device’s headline‑grabbing feature is a metric called Entropy. In physics, entropy measures disorder; in Temple’s context, Goyal claims it is a biomarker that tracks the body’s instantaneous energy use. The system also reports Entropy Maxima and Entropy Minima—peak and trough outputs during intense activity—so users can see how their mental state shifts minute by minute.
Goyal’s enthusiasm stems from a personal struggle. He says he spent more than a decade meditating without measurable progress because conventional health indicators such as heart rate stayed flat. Entropy, he argues, revealed subtle improvements in mental recovery that other metrics missed, giving him the motivation to keep going.
The medical community has responded with caution. An India Today piece from June 2026 noted that doctors questioned the scientific validity of the Entropy claim and that the device had yet to receive regulatory approval. The debate has spilled onto social media, where users and experts alike debate what the sensor actually measures.
Despite the skepticism, Goyal has a launch timetable. Bloomberg reported in July 2026 that he plans to bring Temple to market within six months, targeting a late‑2026 release in India. The product is aimed at the wellness market, offering objective data for those who want to track meditation and cognitive performance.
Today, Temple remains a prototype. No independent validation studies have been published, and regulatory clearance is pending. Goyal continues to use the device personally and shares his data on X, but the broader scientific community awaits peer‑reviewed evidence.
The next steps for Temple will likely involve clinical testing, regulatory approval and a commercial rollout in India. Until then, the device sits at the intersection of ambition and controversy: a tiny headset that promises a new way to measure mental recovery, but one that still needs rigorous scientific validation and regulatory sign‑off.
In short, Deepinder Goyal’s Temple wearable introduces Entropy as a novel metric for meditation recovery. The forehead‑mounted sensor claims to measure cerebral blood flow and oxygenation, and while it has sparked interest, it has also drawn scrutiny from doctors and regulators. The product is slated for launch by the end of 2026, but independent validation and regulatory approval remain outstanding.
Temple is a forehead‑mounted sensor that the co‑founder of Zomato, Deepinder Goyal, says is the world’s smallest wearable. The bean‑shaped device sits on the temple area and promises to deliver real‑time data on focus, fatigue and cognitive performance by measuring cerebral blood flow and oxygenation. Goyal, who earned EY’s Entrepreneur of the Year award in 2025, has long pursued longevity research. He describes Temple as an experimental offshoot of his Gravity Aging Hypothesis work.
The device’s headline‑grabbing feature is a metric called Entropy. In physics, entropy measures disorder; in Temple’s context, Goyal claims it is a biomarker that tracks the body’s instantaneous energy use. The system also reports Entropy Maxima and Entropy Minima—peak and trough outputs during intense activity—so users can see how their mental state shifts minute by minute.
Goyal’s enthusiasm stems from a personal struggle. He says he spent more than a decade meditating without measurable progress because conventional health indicators such as heart rate stayed flat. Entropy, he argues, revealed subtle improvements in mental recovery that other metrics missed, giving him the motivation to keep going.
The medical community has responded with caution. An India Today piece from June 2026 noted that doctors questioned the scientific validity of the Entropy claim and that the device had yet to receive regulatory approval. The debate has spilled onto social media, where users and experts alike debate what the sensor actually measures.
Despite the skepticism, Goyal has a launch timetable. Bloomberg reported in July 2026 that he plans to bring Temple to market within six months, targeting a late‑2026 release in India. The product is aimed at the wellness market, offering objective data for those who want to track meditation and cognitive performance.
Today, Temple remains a prototype. No independent validation studies have been published, and regulatory clearance is pending. Goyal continues to use the device personally and shares his data on X, but the broader scientific community awaits peer‑reviewed evidence.
The next steps for Temple will likely involve clinical testing, regulatory approval and a commercial rollout in India. Until then, the device sits at the intersection of ambition and controversy: a tiny headset that promises a new way to measure mental recovery, but one that still needs rigorous scientific validation and regulatory sign‑off.
In short, Deepinder Goyal’s Temple wearable introduces Entropy as a novel metric for meditation recovery. The forehead‑mounted sensor claims to measure cerebral blood flow and oxygenation, and while it has sparked interest, it has also drawn scrutiny from doctors and regulators. The product is slated for launch by the end of 2026, but independent validation and regulatory approval remain outstanding.
